Literature DB >> 35180829

Impact of Nasolacrimal Dysfunction in Thyroid Cancer Survivors.

Jacqueline Jonklaas1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35180829      PMCID： PMC9271331          DOI： 10.1089/thy.2022.0095

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.506


× No keyword cloud information.
  25 in total

1.  Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma.

Authors:  Richard T Kloos; Vani Duvuuri; Sissy M Jhiang; Kenneth V Cahill; Jill A Foster; John A Burns
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

2.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

3.  Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.

Authors:  Laura Boucai; John Falcone; Jenny Ukena; Catherine C Coombs; Ahmet Zehir; Ryan Ptashkin; Michael F Berger; Ross L Levine; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

4.  Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer.

Authors:  Carrie C Lubitz; Colleen M Kiernan; Asmae Toumi; Tiannan Zhan; Mara Y Roth; Julie A Sosa; R Michael Tuttle; Elizabeth G Grubbs
Journal:  Endocr Pract       Date:  2021-01-16       Impact factor: 3.443

5.  Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients.

Authors:  Kenneth E Morgenstern; Douangsone D Vadysirisack; Zhaoxia Zhang; Kenneth V Cahill; Jill A Foster; John A Burns; Richard T Kloos; Sissy M Jhiang
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2005-09       Impact factor: 1.746

6.  Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.

Authors:  Ju-Yeun Lee; Kyung In Woo
Journal:  Thyroid       Date:  2022-01-11       Impact factor: 6.568

7.  Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction.

Authors:  Jacqueline Jonklaas
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

8.  Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data.

Authors:  Sneha Goswami; Michael Mongelli; Benjamin J Peipert; Irene Helenowski; Susan E Yount; Cord Sturgeon
Journal:  Surgery       Date:  2018-08-24       Impact factor: 3.982

9.  Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Authors:  R J Molenaar; C Pleyer; T Radivoyevitch; S Sidana; A Godley; A S Advani; A T Gerds; H E Carraway; M Kalaycio; A Nazha; D J Adelstein; C Nasr; D Angelini; J P Maciejewski; N Majhail; M A Sekeres; S Mukherjee
Journal:  Leukemia       Date:  2017-11-06       Impact factor: 11.528

10.  Iodine-131 Therapy and Lacrimal Drainage System Toxicity: Nasal Localization Studies Using Whole Body Nuclear Scintigraphy and SPECT-CT.

Authors:  Mohammad Javed Ali; Achyut Ram Vyakaranam; Jyotsna Eleshwarapu Rao; Giri Prasad; Palkonda Vijay Anand Reddy
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 Jan/Feb       Impact factor: 1.746
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.